Arbutus Biopharma

ABUS · NASDAQ

$4.33+$0.10 (+2.36%)TodayMarket closed · Oct 20, 7:46 PM ET

Prev close $4.23

ABUS analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $5.61 (+29.6% upside)

Low: $5.55
Now: $4.33
High: $5.78

Upgrades and downgrades

The latest rating actions, newest first

ABUS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Chardan Capital	Nov 14, 2025	Maintains	Buy	$5.00	38%

The case for and against

Updated Jan 26, 2026

Bull case

Arbutus Biopharma Corp has made significant strides in its clinical development, particularly with imdusiran, which has shown steep and durable declines in HBV DNA, achieving faster suppression rates compared to standard therapy. During the latest financial quarter, Arbutus successfully reduced its R&D expenses by 65%, indicating effective management of operational costs as the company focuses on its promising therapeutics, including AB-101. Additionally, the company recognized a notable revenue increase to $10.7 million for the quarter, up from $1.7 million in the same period of the previous year, showcasing growth and potential market demand for its innovative approaches to treating chronic hepatitis B virus.

Bear case

The negative outlook on Arbutus Biopharma's stock is driven by several fundamental factors. Competition in recruiting patients for clinical programs targeting chronic HBV may hinder the company's progress, affecting its ability to advance therapies. Furthermore, there is a significant risk that the company's RNAi, capsid assembly inhibitors, and HBV RNA destabilizer therapies may fail to meet clinical efficacy endpoints, raising concerns about the viability of its therapeutic pipeline.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.